⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Zapata Quantum Adds Financial Veteran William Klitgaard to Board as Company Aims to Relist on National Exchange
globenewswire.com
ZPTA
XLNX
SYNH
AVST
CERT
BCRA
LHCG
AMZN
GOOG
MSFT
IBM
ORCL
MRK
DGX
ANTM
UNH
AMGN
GILD
BMY
PFE
ABBV
LRCX
KLAC
ADI
NXPI
QCOM
INTC
AMD
NVDA
MU
SMCI
CRWD
PANW
ZS
SNOW
DDOG
FTNT
TEAM
CRM
NOW
ADBE
INTU
PAYX
ADP
CTAS
WBA
CVS
CI
CNC
ELV
REGN
VRTX
BIIB
ALXN
AZN
NVS
ROG
SNY
XRAY
SYK
BSX
TMO
ILMN
EXAS
MDLZ
KHC
PEP
KO
MCD
SBUX
YUM
CMG
QSR
DNKN
LVS
WYNN
MGM
LULU
NKE
UA
ADDYY
PVH
RL
GPS
TJX
ROST
BBY
HD
LOW
SPG
PLD
AMT
EQIX
CCI
SBAC
PLTR
AI
UPST
SOFI
COIN
PYPL
SQ
AXP
V
MA
JPM
BAC
WFC
GS
MS
SCHW
ETFC
RJF
LPLA
BEN
IVZ
ABR
O
PSA
GOOGL
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
globenewswire.com
BIIB
Zenarate Ranked Number 165 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
prnewswire.com
COF
BIIB
VZ
BAC
COST
AET
Alzheimer's Drug Discovery Foundation Launches Milestones in Motion Campaign and Announces Fifth Season of Symposium Series in Palm Beach
prnewswire.com
BIIB
CDNA
New data on lecanemab to be presented at CTAD conference
prnewswire.com
BGXX
ESAIY
BIIB
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
globenewswire.com
BIIB
STOK
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
businesswire.com
STOK
BIIB
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
globenewswire.com
BIIB
IONS
Biogen Completes Acquisition of Alcyone Therapeutics
globenewswire.com
BIIB
IONS
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
globenewswire.com
BIIB